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A B S T R A C T
Background: Mortality in high-risk groups such as people who use illicit drugs is often expressed in relative terms
such as standardised ratios. These measures are highest for diseases that are rare in the general population, such
as hepatitis C, and may understate the importance of common long-term conditions.
Population: 6683 people in community-based treatment for heroin dependence between 2006 and 2017 in
London, England, linked to national hospital and mortality databases with 55,683 years of follow-up.
Method: Age- and sex-specific mortality and hospital admission rates in the general population of London were
used to calculate the number of expected events. We compared standardised ratios (relative risk) to excess deaths
and admissions (absolute risk) across ICD-10 chapters and subcategories.
Results: Drug-related diseases had the highest relative risks, with a standardised mortality ratio (SMR) of 48
(95% CI 42–54) and standardised admission ratio (SAR) of 293 (95% CI 282–304). By contrast, other diseases
had an SMR of 4.4 (95% CI 4.0–4.9) and an SAR of 3.15 (95% CI 3.11–3.19). However, the majority of the 621
excess deaths (95% CI 569–676) were not drug-related (361; 58%). The largest groups were liver disease (75
excess deaths) and COPD (45). Similarly, 80% (11,790) of the 14,668 excess admissions (95% CI 14,382–14,957)
were not drug-related. The largest groups were skin infections (1073 excess admissions), alcohol (1060), COPD
(812) and head injury (612).
Conclusions: Although relative risks of drug-related diseases are very high, most excess morbidity and mortality
in this cohort was caused by common long-term conditions.
1. Introduction
People who use illicit opioids such as heroin have high rates of
mortality and morbidity, with an age-standardised mortality risk of
between four and 15 times the general population (Degenhardt et al.,
2011). In England, people identified as dependent on opiates by drug
treatment and criminal justice services have a six-fold increased risk of
death (Pierce et al., 2015). There are fewer studies of morbidity in this
population, with most focusing on blood borne viral infections and
mental health problems (Aldridge et al., 2018).
Although drug overdose is often found to be the largest single cause
of death among people who are dependent on illicit drugs, it usually
accounts for less than half of deaths overall (Degenhardt et al., 2011;
Gao et al., 2019; Pierce et al., 2015). Available data suggests
cardiovascular disease, respiratory disease, and liver disease also cause
many deaths among people who use drugs, and account for an in-
creasing proportion as age increases (Degenhardt et al., 2014; Merrall
et al., 2013; Pierce et al., 2015). Although these conditions are common
in the general population, their contribution to excess morbidity and
mortality among people who use illicit drugs is unclear.
People who are dependent on illicit drugs have extremely high re-
lative risks of overdose, hepatitis C, HIV and mental health problems.
Some diseases have become specifically associated with illicit drug use,
including hepatitis C in many high income countries. Treatment and
harm reduction initiatives to improve health among people who use
drugs have focused on these areas. In contrast, conditions such as car-
diovascular disease, which may cause greater absolute morbidity and
mortality yet have lower relative risks because they are common in the
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general population, have received less attention. Due to the frequent
disparities between relative and absolute risks in epidemiological stu-
dies, the STROBE guidelines for reporting of observational studies re-
commend reporting both where possible (Vandenbroucke et al., 2014).
However, few studies actually do this (King et al., 2012).
To address this, we have used data from a large cohort of people in
treatment for heroin dependence to compare relative and absolute risks
of hospital admission (as a proxy for morbidity) and death across a
range of disease categories, and reported excess morbidity and mor-
tality in this cohort.
2. Materials and methods
We used data from the Clinical Records Interactive Search resource
at the South London and Maudsley NHS Foundation Trust Biomedical
Research Centre. This is a research repository of anonymised records
derived from the electronic health record system of a mental healthcare
provider in South London, England (Perera et al., 2016). The study
population was 6833 patients aged 18–64 entering community-based
treatment for heroin dependence between 1 January 2006 and 31
March 2017. Patients were linked using NHS number, date of birth, sex
and postcode to inpatient hospital admissions data from the national
Hospital Episode Statistics for England database, and to mortality data
from the Office for National Statistics. Linkage was conducted by NHS
Digital, a public sector statistical agency. Linkage for hospital admis-
sions was conducted until 31 March 2017 and for mortality until 31
January 2019. Some patients have long periods of engagement with the
drug treatment service, while other only attend one appointment, but
data linkage was available for all patients regardless of their engage-
ment with the service.
To allow calculation of reference rates for the general population,
we also accessed hospital admission data for all residents in the
healthcare provider’s catchment area of the London Boroughs of
Croydon, Lambeth, Lewisham and Southwark, and the number of
deaths by age group, sex and cause for all residents of London from the
Office for National Statistics. Denominators for the relevant general
populations were derived from publicly available population estimates
(Office for National Statistics, 2017). The reference data were accessed
for 2006–2016 as the closest available match to the study cohort.
For descriptive purposes, we reported drug use according to stan-
dard National Drug Treatment and Monitoring System (NDTMS, Public
Health England and Department of Health, 2017) forms collected by the
service provider. These data are collected for each patient at entry to
the service, treatment reviews and at discharge. We identified patients
as heroin users where heroin was listed on any NDTMS form collected
during the study period. Poly-drug use is common in this cohort and we
also reported other drugs that were listed for at least 10% of patients.
Where any NDTMS form listed ‘currently injecting’, we classified the
patient as ‘reported injecting during the study’.
2.1. Disease categories
We used a two-level hierarchy to classify deaths. First, we grouped
deaths according to the ICD-10 chapter (World Health Organization,
2016) of the underlying cause of death (such as ‘respiratory diseases’).
Chapters with fewer than 10 deaths during the study period were
grouped together under ‘other’. Second, we grouped deaths according
to three-character subcategories (such as ‘influenza and pneumonia’),
again grouping subcategories with fewer than 10 deaths under ‘other’.
We used a similar process to group hospital admissions, classifying
admissions based on the primary diagnosis and classifying categories
with fewer than 250 admissions under ‘other’. For both mortality and
hospital admissions, we separated out ‘drug-related’ events, using the
Office for National Statistics definition (Office for National Statistics,
2018) (see Supplementary Material). This identified events where the
main cause related directly to the use of illicit drugs. In the mortality
data, these events are most commonly overdoses, and are more diverse
for hospitalisations, including intoxication and drug withdrawal.
2.2. Calculation of relative and absolute risks
We calculated reference rates for death and hospital admission in
the general population within sex and age groups (18–24, 25–34,
35–44, 45–54 and 55–64) for each disease. We then calculated the
expected numbers of events by applying these reference rates to the
study population, with time-at-risk calculated for each stratum and
accounting for individuals aging during the study. We calculated
standardised mortality ratios (SMRs) and standardised admission ratios
(SARs) by dividing observed events by expected events (i.e. indirect
standardisation). Excess events were calculated as the observed minus
the expected events. A formula for calculating the excess events is
provided in the Supplementary Material, together with a worked ex-
ample including analysis code.
We calculated 95% confidence intervals using the exact poisson
method (Garwood, 1936). We also used the Kaplan-Meier method to
estimate the risk of all-cause death over ten years.
All analyses were conducted using R version 3.5.1.
3. Results
3.1. Cohort characteristics
Most patients were aged 25–44 and three-quarters were male, re-
flecting the demographics of patients entering treatment for opiate
dependence nationally (Public Health England and Department of
Health, 2017). The majority of patients (72%) used crack cocaine as
well as heroin. Use of alcohol, cannabis, and benzodiazepines was also
recorded for more than 10% of patients. One in three reported injecting
during follow-up, though this is likely to be a lower-bound because
patients may not want to disclose injecting while they are prescribed
opiate substitution therapy. The cohort characteristics are summarised
in Table 1.
3.2. Mortality
During 55,639 years of follow-up (median 9.4, range 0–13), there
were 732 deaths, giving a crude all-cause mortality rate of 132/10,000
person-years and an SMR of 6.6 (95% CI 6.1–7.1). There were 621
excess deaths (95% CI 569–676). A Kaplan-Meier estimate suggested
Table 1
Cohort characteristics for 6683 people who use heroin.
Variable Level Number of participants
(%)
Age at first treatment episode 18–25 552 (8)
25–34 2259 (34)
35–44 2568 (38)
45–54 1099 (16)
55–64 205 (3)
Sex Female 1727 (26)
Male 4956 (74)
Ethnicity White 5260 (79)
Black 803 (12)
Mixed 212 (3)
Asian 204 (3)
Other/unknown 204 (3)
Other drugs Crack cocaine 4813 (72)
Alcohol 2961 (44)
Cannabis 1628 (24)
Benzodiapines 747 (11)
Reported injecting during the study Yes 2335 (35)
No 4348 (65)
Total 6683 (100)
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that 12.6% (95% CI 11.7%–13.5%) of patients would have died after 10
years of follow-up, with 2800 remaining in the risk set.
Of the 621 excess deaths, 260 (42%) were drug-related and 361
(58%) were due to other causes. The SMRs were 48 (95% CI 42–54) for
drug-related deaths and 4.4 (95% CI 4.0–4.9) for all other causes
combined. Among ICD-10 chapters, digestive diseases caused the most
excess deaths (97), followed by respiratory disease (58) and external
causes (46). The largest subcategories were liver disease (75), COPD
(45) and accidents (30). The number of deaths and excess deaths are
summarised in Fig. 1, with full results are given in Supplementary
Material, including comparisons to existing studies.
3.3. Hospital admissions
During 44,590 years of follow-up (median 7.7, range 0–11), there
were 21,494 hospital admissions, giving a crude admission rate of 482/
1,000 person-years and a SAR of 3.15 (95% CI 3.11–3.19). There were
14,668 excess admissions (95% CI 14,382–14,957).
Of the 14,668 excess admissions, 3042 (20.7%) were drug-related
and 11,790 (80.3%) were primarily related to other causes. The SARs
were 293 (95% CI 282–304) for drug-related admissions and 2.77 (95%
CI 2.73–2.81) for all other causes. Among ICD-10 chapters, mental and
behavioural disorders caused the most excess admissions (2055), fol-
lowed by digestive diseases (1940) and external causes (1685). The
largest subcategories were mental and behavioural disorders due to
alcohol (1060 excess admissions), COPD (812), head injury (612), and
diseases of the oral cavity, predominantly dental caries (516).
4. Discussion
We conducted a population-based cohort study of people who use
heroin and had at least one contact with community-based drug
treatment services. Consistent with existing studies of similar popula-
tions, our cohort had extreme risk of hospitalisation and death. The
majority of excess morbidity and mortality in this population related to
common non-communicable diseases.
The use of ‘excess events’ shows the breadth of important diseases in
this group, in contrast to the use of relative risks alone, which prioritise
drug-related events, blood-borne viruses and mental health problems.
The analysis of mortality highlights the importance of digestive, re-
spiratory and cardiovascular diseases, and external causes such as ac-
cidents. The analysis of hospital admissions shows that the excess
burden of non-communicable diseases is four times greater than for
drug-related conditions, and particularly highlights the importance of
liver disease, COPD, dental caries and head injuries. Although we
provide a more detailed break-down than previous studies, our results
are broadly consistent with existing research (Merrall et al., 2013,
2012; Pierce et al., 2015). The literature on health inequalities gen-
erally focuses on relative risks, with few studies reporting both relative
and absolute risks (King et al., 2012). Our results provide an example of
the radically different effects when relative and absolute risks are
compared.
We used a linkage system with national mortality and hospital da-
tabases, which is important because the study population is likely to be
mobile and local databases underestimate the rate of events. A limita-
tion of the analysis is that hospital admissions capture a severe aspect of
morbidity, and further research should examine primary care data to
provide a more detailed picture. Our data included information on a
range of drugs recorded by the drug treatment service, but did not
provide detailed information on routes of administration. Three-quar-
ters of patients used both heroin and crack cocaine, but the data does
not show whether patients used these drugs separately or mixed them
together as ‘speedballs’.
The mortality and hospital admission results showed some different
Fig. 1. Number of deaths and hospital admissions in a cohort of 6683 people who use heroin in South London, 2016–2019. The area of the circles is proportional to
the number of events, while the dark sections show the number of excess events.
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patterns. For example, patients in our cohort were twice as likely to die
due to cancer compared to the general population, but were half as
likely to be admitted to hospital for cancer treatment. The lower-than-
expected rate of hospital admission related to cancer has also been
observed for opiate users in Scotland (Merrall et al., 2013). The reasons
for this are not clear, but may relate to poorer diagnosis of cancer
among people who use heroin, or delayed help-seeking when symptoms
occur. Our data also suggest that blood-borne viruses are a common
cause of death (5%) but a rare cause of hospitalisation (< 1%). This
may partly relate to coding practices, as the primary cause of hospita-
lisation for patients with viral hepatitis or HIV may be listed as some-
thing else, such as liver disease or an AIDS-defining illnesses.
The pattern of causes of morbidity and mortality is related to age. In
older cohorts of people who use illicit drugs, non-communicable dis-
eases cause larger proportions of deaths (Degenhardt et al., 2014) and
relative mortality risks reduce as the reference rates in the general
population increase. There may also be secular changes. For example,
in cohorts of people who use heroin in Sweden (Nyhlén et al., 2011)
and the UK (Oppenheimer et al., 1994) recruited in the 1960s and 70 s
and followed-up until the 1990s, more than half of deaths were drug-
related. These higher proportions of drug-related mortality may relate
to more limited harm reduction services, which were rolled-out in the
1980s and 90 s in many high-income countries. There is some evidence
that the average age of people seeking treatment for heroin dependence
is increasing (Public Health England and Department of Health, 2017)
and the importance of non-communicable diseases is also likely to in-
crease.
Interventions designed to improve the health of people who use
heroin have focused on prevention and treatment of blood-borne viral
infections and overdoses, as well as reduction in drug-related crime.
Needle and syringe programmes, take-home naloxone and opiate sub-
stitution are well-researched and effective interventions that target
these outcomes (Amato et al., 2005; European Monitoring Centre for
and Drugs and Drug Addiction, 2015; Platt et al., 2017). However, there
are few interventions that aim to prevent and treat common non-
communicable diseases in this group. Our results demonstrate the ur-
gent need for research in this area.
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